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K ATP channels regulate insulin secretion by coupling β-cell metabolism to membrane excitability. These channels are
comprised of a pore-forming Kir6.2 tetramer which is enveloped by four regulatory SUR1 subunits. ATP acts on Kir6.2 to
stabilize the channel closed state while ADP (coordinated with Mg2+) activates channels via the SUR1 domains. Aberrations
in nucleotide-binding or in coupling binding to gating can lead to hyperinsulinism or diabetes. Here, we report a case
of diabetes in a 7-mo old child with compound heterozygous mutations in ABCC8 (SUR1[A30V] and SUR1[G296R]). In
unison, these mutations lead to a gain of K ATP channel function, which will attenuate the β-cell response to increased
metabolism and will thereby decrease insulin secretion. 86Rb+ flux assays on COSm6 cells coexpressing the mutant
subunits (to recapitulate the compound heterozygous state) show a 2-fold increase in basal rate of 86Rb+ efflux relative
to WT channels. Experiments on excised inside-out patches also reveal a slight increase in activity, manifested as an
enhancement in stimulation by MgADP in channels expressing the compound heterozygous mutations or homozygous
G296R mutation. In addition, the IC50 for ATP inhibition of homomeric A30V channels was increased ~6-fold, and was
increased ~3-fold for both heteromeric A30V + WT channels or compound heterozygous (A30V + G296R) channels. Thus,
each mutation makes a mechanistically distinct contribution to the channel gain-of-function that results in neonatal
diabetes, and which we predict may contribute to diabetes in related carrier individuals.
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Introduction

ATP sensitive potassium (K ATP) channels are widely distributed in
various tissues and cell types where they couple cell metabolism to
cell excitability and therefore play important physiological roles.1
The gating properties that are critical for the physiological function
of K ATP channels are their sensitivity to intracellular nucleotides
ATP and ADP, whose concentrations fluctuate as glucose levels
vary. Both Kir6.x and SUR subunits participate in nucleotide regulation of the channel; ATP inhibits channel activity by binding
to the Kir6.x subunits, whereas Mg2+ -complexed ATP and ADP
stimulate channel activity by interacting with SUR subunits. For
pancreatic β cells, upon an increase in glucose concentration, K ATP
channels are driven to closure by the increase in ATP/ADP ratio,
resulting in membrane depolarization. The depolarization activates
voltage-gated calcium channels and causes insulin secretion.2-4
Over 65 gain-of-function mutations in K ATP channels
genes resulting in neonatal diabetes (NDM) have now been

identified. These mutations result in overactive channels, leading to hyperpolarization of β cells and reduced insulin secretion.
Sulfonylureas, which specifically inhibit the K ATP channel by
interacting with SUR subunits, can restore insulin secretion in
these patients.5-8 Such mutations in K ATP channels account for
approximately 50% of all cases of permanent neonatal diabetes
and while mutations in KCNJ11, encoding Kir6.2, are more commonly inherited in an autosomal dominant pattern, in 43% of
cases, ABCC8-related permanent neonatal diabetes is inherited
in an autosomal recessive manner from unaffected parents with
heterozygous mutations.9 Increased activity of K ATP channels
resulting from mutations in ABCC8 is caused by an increase in
the magnesium-dependent stimulatory action of SUR1 on the
pore8,10 or by alteration in the inhibitory action of ATP on the
Kir6.2 subunit.11 Here we report the case of a child with permanent neonatal diabetes due to novel compound heterozygous
mutations in ABCC8 and the functional characterization of these
mutant channels.
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Results
Case report and identification of the compound heterozygous
mutations in ABCC8. A 7-mo-old Pakistani male presented with
diabetic ketoacidosis. He was born via vaginal delivery, with
birth weight of 3.416 kg and birth length was 48.9 cm (both
appropriate for gestational age). At presentation he had fever,
increased irritability and Kussmaul breathing. His weight was
9 kg (95th percentile), and he was severely dehydrated. Laboratory
studies showed a pH of 7.06, bicarbonate of 5 mmol/L, glucose
of 750 mg/dL (41.7 mmol/L), and HgA1c of >14%. He was fluid
resuscitated and started on 0.1 unit/kg/hour of intravenous insulin. His acidosis resolved within 24 h and he was transitioned to
a subcutaneous regimen of intermediate (NPH) and rapid-acting (aspart) insulin at a total daily dose of 0.6–0.8 unit/kg/day.
Family history was remarkable for history of diabetes in maternal grandparents who were diagnosed in their 40s and treated
with oral medications. The paternal grandfather was recently
diagnosed with diabetes in his 50s and is also on oral medications. The mother had 2 h OGTT during pregnancy which was
reported as normal and there is no history of diabetes in the
father although he has not been tested. After starting subcutaneous insulin regimen, the proband HgA1c improved to 9.7%. A
diabetes autoimmune panel, obtained after initiation of insulin,
was weakly positive for insulin antibodies at 5.4 uU/mL (normal
0–5), and negative for GAD 65 and CA 512 antibodies (<0.5 U/
mL and <0.8 U/mL, respectively). Direct sequencing of his DNA
revealed two mutations in the ABCC8 gene c.886 G > A (G296R)
and c.89 C > T (A30V), the first of which is maternally derived
and the second is paternally derived. Neither of these mutations
has been previously described. At 12 mo of age, he was started
on 0.2 mg/kg/day of glibenclamide (glyburide), increasing daily,
until he was weaned off insulin, to a dose of 0.35 mg/kg/day.
Baseline fasting C-peptide (prior to initiation of glibenclamide)
was 0.119 ng/mL (blood glucose 118 mg/dL) and increased to 1.4
ng/mL (blood glucose 101 mg/dL) on glibenclamide. Four weeks
after initiation of glibenclamide his HgA1c improved to 6.4%,
random insulin level was 6.5 μU/mL and C-peptide was 1.71 ng/
mL (blood glucose 82 mg/dL). He has maintained good control
with HgA1c in the range of 4.8–6.4% since initiation of therapy
with glibenclamide.
Compound heterozygous mutant channel are more active in
whole cells. To test the hypothesis that the compound heterozygous channels have an overall gain of channel function in intact
cells, we examined 86Rb+ efflux across the plasma membrane in
COSm6 cells cotransfected with Kir6.2 and WT or mutant SUR1.
Efflux curves were fit with a two-pathway model (see materials and
methods); untransfected cells providing the efflux rate (k1) for the
non K ATP pathway and the indication of channel activity, k 2, is
calculated from transfected cells. As shown in Figure 1A, neither
heteromeric single mutant channels ([A30V + WT], referred to
as hetA30V and [G296R + WT], referred to as hetG296R) nor
compound heterozygous channels ([A30V + G296R]) exhibited
significantly different maximum 86Rb+ efflux rates in the presence
of metabolic inhibitors. However, in basal conditions without metabolic inhibitors, compound heterozygous but not single mutant
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Figure 1. Increased basal K ATP activity in compound heterozygous channels compared with WT channels. 86Rb+ efflux of heterozygous mutant
channels coexpressed with each other or WT in 1:1 DNA ratio. NT:Non
Transfected cells. The NT curve is used to calculate the non K ATP channel
pathway rate k1 (see Materials and Methods). (A) In the presence of
metabolic inhibition, compound heterozygous and hetA30V, hetG296R
channels exhibit similar maximal Rb efflux rates. (B) Compound heterozygous channels display a 2-fold increase in the basal 86Rb+ efflux without metabolic inhibitors. Data points indicate means ± SEM of n = 4–9
experiments. Fitted lines correspond to least squares fits of a doubleexponential equation.*p < 0.05 compared with WT by One-Way ANOVA
analysis. (C) Rate constant for K ATP-dependent 86Rb+ efflux (k 2) in basal
conditions relative to metabolic inhibition (MI). k 2,basal/k 2,MI calculated
from WT, het A30V, het G296R and SUR1[A30V + G296R] are 0.07 ± 0.005,
0.08 ± 0.01, 0.1 ± 0.01 and 0.16 ± 0.01 (n = 4–9). *p < 0.05 compared with
WT by One-Way ANOVA analysis.

heterozygous channels exhibit significantly increased k 2 compared
with WT channels (Fig. 1B and C). The increased 86Rb+ efflux
rate in the compound heterozygous channels indicates that they
have higher channel activity when both mutants are present from
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Figure 2. Membrane topology of SUR1 and the predicted locations of
A30V and 296R. The red filled circles indicate the predicted positions
for A30V at the N terminus of its 1st transmembrane domain (TMD0)
and G296R at the L0 linker region before TMD1 domain. L0 is colored in
orange.

each allele and reflects a recessive effect of the two mutations that
will manifest as significantly increased K ATP conductance only in
the compound heterozygous case, as in the proband.
HetG296R channels exhibit increased sensitivity to MgADP
stimulation while HetA30V channels exhibit slightly decreased
ATP sensitivity. A30V and G296R mutants are located at the
TMD0 and the cytosolic linker region (L0) of SUR1 3 (Fig.
2). The TMD0 and L0 domains at the beginning of the SUR1
protein have been proposed to interact with the Kir6.2 subunit
and to functionally couple the core nucleotide binding domains
(NBD1 and NBD2) to the channel pore.8,12-17 Because of the
functional/physical coupling between SUR1 and Kir6.2, any
mutant in SUR1 could affect the intrinsic channel gating of
Kir6.2 or simply affect the transduction of Mg-nucleotide stimulation. Here we characterized the sensitivity to MgADP activation, as well as inhibitory ATP sensitivity (without Mg2+), of
homomeric A30V channels (labeled as homA30V), homomeric
G296R channels (labeled as homG296R), hetA30V, hetG296R
and compound heterozygous channels [A30V + G296R].8,18,19
Representative recordings of channel response to MgADP from
WT and compound heterozygous mutants are shown in Figure
3A and summary results are shown in Figure 3B. Homomeric
G296R channels exhibit dramatically increased MgADP activity, while homomeric A30V channels show no significant
enhancement (Fig. 3B). However, hetG296R and compound
heterozygous channels show a small but not significant increase
in MgADP stimulation. On the other hand, it is noticeable that
A30V homomeric channels show significant increased current in
0.1 mM MgATP, reflecting an additive consequence of the two
distinct mutant effects (Fig. 3B).
ATP response of WT and mutant channels. Given that
homomeric A30V channels showed greatly reduced ATP sensitivity in 0.1 mM ATP (with 0.5 mM free Mg2+), we characterized the sensitivity to inhibitory ATP, without any confounding
effects of Mg-nucleotides. Representative recordings of channel
response to different concentrations of ATP from WT, homA30V,
homG296R and compound heterozygous mutants are shown in
Figure 4A. Correspondingly, homA30V channels exhibit significantly reduced ATP sensitivity compared with WT channels. A
summary of the ATP dose response-curves for WT and mutant

© 2012 Landes Bioscience.
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Figure 3. Analysis of response to MgADP. Representative inside-out
patch clamp recordings of WT and A30V + G296R in different MgATP
and MgADP concentrations (A). Mg2+ is included in all ATP-containing
solutions (free Mg2+ = 0.5 mM). (B) Relative channel currents in 0.1
mM MgATP and plus 0.5 mM MgADP for WT, homA30V, homG296R, hetA30V, hetG296R and compound heterozygous [A30V + G296R] channels
as indicated. Each bar is the mean ± SEM (n = 4–9). *p < 0.05 compared
with WT by One-Way ANOVA analysis.

channels is shown in Figure 4B. Homozygous G296R channels
exhibit a slightly right-shifted dose-response, but homozygous
A30V channels exhibit a marked and significantly right-shifted
ATP sensitivity (Fig. 4B). In the heteromeric case, mimicking the
disease condition, hetG296R channels are not markedly different
from WT, but hetA30V and compound heterozygous A30V +
G296R channels both exhibit a significant rightward shift when
compared with WT channels (Fig. 4C).
The compound heterozygous mutation does not alter sulfonylurea sensitivity of the channel. Because some Kir6.2
mutations can significantly change sulfonylurea (SU) sensitivity,22,25 we examined the SU sensitivity of these mutations.
Representative recordings of channel response to different
concentrations of glibenclamide are shown in Figure 5A. A
summary of the relative current in different concentrations of
glibenclamide are shown in Figure 5B. Glibenclamide sensitivity was not significantly altered in the compound heterozygous
channel. Consistent with this, the patient responded to oral
sulfonylurea glibenclamide and he was weaned off insulin, at a
dose of 0.35 mg/kg/day.
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Figure 4. ATP-response curves of WT and mutant channels. (A) Representative currents recorded by inside-out excised patch-clamp technique from
COSm6 cells expressing WT, homA30V, homG296R and [A30V + G296R] at +50 mV pipette potential. Patches were exposed to different concentrations
of Mg-free ATP as indicated. (B) ATP dose-response relationships, fit by Hill equation as described in methods. Data points indicate means ± SEM of n =
6–9 patches. *p < 0.05 compared with WT by One-Way ANOVA analysis. Fitted K1/2 for WT, homA30V and homG296R channels are 9.65, 53.31 and 28.11
(in μM) and the Hill coefficients are 1.22, 1.04 and 1.19, respectively. (C) The fitted K1/2 for WT, hetA30V, hetG296R and [A30V + G296R] are 9.65, 25.75,
12.75 and 25.45 (in μM) and the Hill coefficients are 1.22, 1.28, 1.29 and 1.23, respectively.

Discussion
Clinical case. We have described the case of a child presenting
with diabetic ketoacidosis at 7 mo of age. Although the standard
definition of neonatal diabetes refers to diabetes presenting in the
first 6 mo of life,20 not uncommonly, like in our case, presentation is beyond this age, prompting some to propose to replace
the term “neonatal diabetes mellitus” with “diabetes mellitus of
infancy”.21 Each ABCC8 mutation carried by this child makes a
unique contribution to enhancement of channel activity, resulting
in marked stimulation of basal Rb efflux only in the compound
heterozygous case (Fig. 1B and C), and explaining the presentation of the disease in the proband, as well as the responsivity
to sulfonylureas.22,23 The G296R mutation is inherited from the
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patient’s mother who is normal in her OGTT, but it is noticeable
that the both maternal grandparents and the paternal grandfather
reportedly have Type-2 Diabetes, which might come from a high
risk of predisposition conferred by the heterozygous mutation in
ABCC8, even though previous studies have indicated that carrier
parents of similarly inherited compound heterozygous mutations
are non-diabetic.24 Thus we may speculate that similar carriers of
individual variants such as this may be predisposed to diabetes.
Interestingly, the G296R variant was identified as a rare variant
in whole exome sequencing of over 1,000 individuals (http://evs.
gs.washington.edu/EVS/).
Importance of TMD0 and L0 domains of SUR1 in regulating Kir6.2 subunits. A30 and G296 are located in the TMD0
and L0 domain, which has been proposed to confer SUR1
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from the child and both parents. The 39
exons of ABCC8 were directly sequenced.
Two mutations were found in ABCC8 in the
proband: c.886 G > A, predicted to cause a
G296R amino acid change, was maternally
transmitted, and c.89 C > T, predicted to
cause A30V amino acid change, was paternally transmitted. DNA from 54 healthy
control subjects was screened for these
mutations and they were negative. Hamster
SUR1 was cloned into the pECE vector
and the parental plasmid DNA was used
to generate SUR1 mutations using the
QuickChange Site Directed Mutagenesis
Kit (Stratagene) The mutation was confirmed by further sequencing. The mouse
Kir6.2 was cloned into the pCDNA3.1 vector (Invitrogen).
Expression of K ATP channels in COSm6
cells. COSm6 cells were cultured and
transfected with cDNA using FuGENE 6
Transfection Reagent (Roche Diagnostics)
as previously described in reference 10.
Green fluorescent protein (as a marker
for positive transfection) was mixed with
FuGENE 6 and preincubated for 1 h. Cells
were incubated in the presence of the transfection mixture for 18–30 h, and plated
Figure 5. Glibenclamide sensitivity of WT and mutant channels. (A) Representative currents
on sterile glass coverslips overnight before
recorded by inside-out excised patch-clamp technique from COSm6 cells expressing WT and
patch-clamp experiments.
[A30V + G296R] at +50 mV pipette potential. Patches were exposed to different concentrations
86
Rb + efflux assay. COSm6 cells transof glibenclamide as indicated (free Mg-nucleotide). (B) Current in different concentrations of
fected with GFP, SUR1 and Kir6.2 cDNA
glibenclamide relative to control solution (zero glibenclamide). Data points indicate means ±
were incubated for 5–12 h in culture medium
SEM of n = 4–6 patches.
containing 86RbCl (1 μCi/ml) 24 h posttransfection. Before measurement of 86Rb +
10,14,17
ligand-independent channel gating of Kir6.2.
More spe- efflux, cells were incubated for 5 min at room temperature in
cifically, SUR1 fragments lacking the TMD0 domain failed to Krebs-Ringer solution with metabolic inhibitors (2.5 μg/ml olimodulate Kir6.2 activity, which suggests a potential physical gomycin and 1 mM 2-deoxy-D-glucose). At selected time points
interaction between TMD0 of SUR1 and the N terminus of the solution was aspirated from the cells and replaced with fresh
Kir6.2. The cytosolic linker L0 domain has also been proposed solution. At the end of a 40 min period, the cells were lysed with
to directly transduce the Mg-nucleotide stimulatory action from 2% SDS. The 86Rb + in the aspirated solution and the cell lysate
the SUR1 core to the Kir6.2 pore14 and a previous study demon- was counted. The percentage efflux at each time point was calcustrated that another NDM mutation (L213R) in the L0 region lated as the cumulative counts in the aspirated solution divided
also shifts intrinsic ATP sensitivity.13 The present study thus pro- by the total counts from the solutions and the cell lysates. 86Rb +
vides further evidence that mutations in the TMD0-L0 region efflux curves were fitted by assuming that a single non-K ATP conalter the K ATP channel activity and further supports the hypoth- ductance was active in the untransfected cells, using the equaesis that TMD0-L0 is closely associated with Kir6.2.
tion, Eq.1 Rb efflux = 1 - Exp (-k1·t) where exp is an exponential
function, t is time, and k1 is the rate constant for efflux through
Materials and Methods
the endogenous, non-K ATP pathway. In transfected cells, efflux
curves were fitted by assuming that both a K ATP and a non-K ATP
Clinical data. Clinical information was obtained by chart conductance pathway were active in parallel and were deterreview. The study was approved by The Children’s Hospital of mined as Eq.2 Rb efflux = 1 - Exp[(-k1 + k 2)·t] where k1 is the rate
Philadelphia Institutional Review Board. Informed consent was constant for efflux through the endogenous, non-K ATP pathway
obtained from the parents of the child.
(obtained from untransfected cells by Eq. 1) and k 2 is the rate
Genetics and molecular biology. Genomic DNA was pre- constant for efflux through the K ATP pathway. k 2 is then directly
pared from peripheral blood white cells or oral mucosa cells proportional to the K ATP conductance.
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Electrophysiological methods. Membrane patches were
voltage-clamped and currents were measured at a membrane
potential of -50 mV (pipette voltage, +50 mV), with inward currents shown as upward deflections. Data were collected using the
pClamp 8.2 software suite (Axon Instruments) and Microsoft
Excel (Microsoft). The bath (intracellular) and pipette (extracellular) solution (K-INT) had the following composition: 140 mM
KCl, 10 mM Hepes, 1 mM EGTA, pH 7.4. ATP was added as
the dipotassium salt.
Quantitative analysis of ATP inhibition. Channels in insideout patches were exposed to varying concentrations of ATP in
K-INT solution. Channel activity was normalized to that seen
in the absence of ATP. The curves were fit by the Hill equation
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